Organometallics
Article
silver(I) oxide (35 mg, 0.15 mmol, 0.50 equiv), and palladium(II)
bromide (80 mg, 0.30 mmol, 1.00 equiv). The product was obtained as
a yellow solid (173 mg, 0.29 mmol, 98%). NMR spectra could not be
obtained due to the low solubility of the compound in all common
deuterated solvents and the fluxionality of its structure. Mp: 170 °C
C H Br N PdS: C, 46.76; H, 5.68; N, 7.52. Found: C, 46.83; H,
29
42
2
4
+
5.59; N, 7.48. MS (ESI): m/z 665 [M − Br] .
trans-Dibromido(1-benzhydryl-3-(2-(isopropylthio)ethyl)-
benzimidazolin-2-ylidene)(1,3-diisopropylbenzimidazolin-2-
ylidene)palladium(II) (15). The compound was prepared in analogy to
1
3 from 3 (207 mg, 0.44 mmol, 1.00 equiv), silver(I) oxide (51 mg,
(
dec). Anal. Calcd for C H Br N PdS: C, 40.67; H, 4.10; N, 4.74.
20 24 2 2
i
+
0.22 mmol, 0.50 equiv), and [PdBr ( Pr -bimy)] (206 mg, 0.22 mmol,
Found: C, 40.21; H, 4.28; N, 4.57. MS (ESI): m/z 511 [M − Br] .
2 2 2
0
.50 equiv). The product was obtained as a yellow solid (229 mg, 0.27
cis-Dibromido(1-isobutyl-3-(3-(isopropylthio)propyl)-
2
1
benzimidazolin-2-ylidene-κ C,S)palladium(II) (11). The compound
mmol, 61%). H NMR (500 MHz, CDCl
7.60−7.57 (m, 1 H, Ar−H), 7.55−7.52 (m, 1 H, Ar−H), 7.44−7.34
(m, 11 H, Ar−H, NCHPh ), 7.22−7.18 (m, 3 H, Ar−H), 6.95 (t,
): δ 8.61 (s, 1 H, Ar−H),
3
was prepared in analogy to 4 from 8 (111 mg, 0.30 mmol, 1.00 equiv),
silver(I) oxide (35 mg, 0.15 mmol, 0.50 equiv), and palladium(II)
bromide (80 mg, 0.30 mmol, 1.00 equiv). The product was obtained as
a yellow solid (167 mg, 0.30 mmol, >99%). NMR spectra could not be
obtained due to the low solubility of the compound in all common
deuterated solvents and the fluxionality of its structure. Mp: 218 °C
2
3
3
J
H−H = 8 Hz, 1 H, Ar−H), 6.67 (d, JH−H = 8 Hz, 1 H, Ar−H), 6.24
3
3
(sept, JH−H = 7 Hz, 1 H, NCH), 6.02 (sept, JH−H = 7 Hz, 1 H,
), 3.12
NCH), 5.13−5.06 (m, 2 H, NCH
), 3.52−3.46 (m, 2 H, SCH
2
2
3
3
(sept, JH−H = 7 Hz, 1 H, SCH), 1.85 (d, JH−H = 7 Hz, 3 H, CH
),
).
3
3
3
(
dec). Anal. Calcd for C H Br N PdS: C, 36.68; H, 4.71; N, 5.03.
1.67 (d, JH−H = 7 Hz, 3 H, CH
3
), 1.37 (d, JH−H = 7 Hz, 3 H, CH
3
17
26
2
2
+
13
1
Found: C, 36.27; H, 4.55; N, 5.40. MS (ESI): m/z 1032 [M − Br] .
C{ H} NMR (125 MHz, CDCl
3
): δ 186.3 (Ccarbene), 179.2 (Ccarbene),
cis-Dibromido(1-benzhydryl-3-(2-(isopropylthio)propyl)-
138.9, 135.6, 134.8, 134.3, 134.2, 129.6, 129.2, 128.7, 123.4, 122.6,
2
benzimidazolin-2-ylidene-κ C,S)palladium(II) (12). The compound
114.3, 113.4, 113.3, 110.9 (Ar−C), 68.3 (NCH Ph), 54.8 (NCH), 54.5
2
was prepared in analogy to 4 from 9 (144 mg, 0.30 mmol, 1.0 equiv),
silver(I) oxide (35 mg, 0.15 mmol, 0.50 equiv), and palladium(II)
bromide (80 mg, 0.30 mmol, 1.00 equiv). The product was obtained as
a yellow solid (200 mg, 0.30 mmol, >99%). NMR spectra could not be
obtained due to the low solubility of the compound in all common
deuterated solvents and the fluxionality of its structure. Mp: 181 °C.
Anal. Calcd for C H Br N PdS: C, 46.83; H, 4.23; N, 4.20. Found:
(NCH), 49.1 (NCH ), 36.3 (SCH), 30.4 (SCH ), 24.4 (CH ), 21.7
2
2
3
(CH ), 21.5 (CH ). Mp: 136 °C. Anal. Calcd for C H Br N PdS·
3
3
38 44
2
4
0.5CH Cl : C, 51.52; H, 5.05; N, 6.24. Found: C, 51.75; H, 5.20; N,
2
2
+
6.35. MS (ESI): m/z 775 [M − Br] .
trans-Dibromido(1-benzyl-3-(2-(isopropylthio)propyl)-
benzimidazolin-2-ylidene)(1,3-diisopropylbenzimidazolin-2-
ylidene)palladium(II) (16). The compound was prepared in analogy to
2
6
28
2
2
+
C, 46.68; H, 4.30; N, 4.15. MS (ESI): m/z 585 [M − Br] .
13 from 7 (405 mg, 1.00 mmol, 1.00 equiv), silver(I) oxide (116 mg,
i
trans-Dibromido(1-benzyl-3-(2-(isopropylthio)ethyl)-
benzimidazolin-2-ylidene)(1,3-diisopropylbenzimidazolin-2-
ylidene)palladium(II) (13). Salt 1 (391 mg, 1.00 mmol, 1.00 equiv)
and silver(I) oxide (116 mg, 0.50 mmol, 0.50 equiv) were suspended
in dichloromethane (15 mL) and stirred at ambient temperature for 15
0.50 mmol, 0.50 equiv), and [PdBr
2
( Pr
2
-bimy)]
2
(469 mg, 0.50 mmol,
0.50 equiv). The product was obtained as a yellow solid (485 mg, 0.61
1
mmol, 61%). H NMR (500 MHz, CDCl ): δ 7.73−7.69 (m, 2 H, Ar−
3
H), 7.66−7.63 (m, 1 H, Ar−H), 7.60−7.56 (m, 2 H, Ar−H), 7.47−
7.43 (m, 2 H, Ar−H), 7.40−7.36 (m, 1 H, Ar−H),7.34−7.30 (m, 2 H,
i
h shielded from light. [PdBr ( Pr -bimy)] (469 mg, 0.50 mmol, 0.50
Ar−H), 7.28−7.26 (m, 1 H, Ar−H), 7.25−7.20 (m, 2 H, Ar−H), 6.29
2
2
2
3
equiv) was suspended in dichloromethane (20 mL), and the filtered
silver carbene complex solution was added to this suspension. The
resulting mixture was stirred for 1 h at ambient temperature. Then it
was filtered and concentrated under reduced pressure. The residue was
purified by column chromatography (silica, dichloromethane + 5%
(sept, J
= 7 Hz, 1 H, NCH), 6.22 (s, 2 H, NCH Ph), 6.08 (sept,
H−H 2
3
JH−H = 7 Hz, 1 H, NCH), 5.10−5.05 (m, 2 H, NCH ), 3.07 (sept,
= 7 Hz, 1 H, SCH), 2.87 (t, J
.63 (m, 2 H, CH ), 1.93 (d, J
2
3J
2
=
3
= 7 Hz, 2 H, SCH ), 2.71−
H−H
3
H−H
2
3
= 7 Hz, 6 H, CH ), 1.69 (d, J
2
H−H
3 H−H
3
13
1
7 Hz, 6 H, CH ), 1.39 (d, J
= 7 Hz, 6 H, CH3). C{ H} NMR
3
H−H
EtOH). The product was obtained as a yellow solid (644 mg, 0.83
(
125 MHz, CDCl ): δ 184.1 (Ccarbene), 178.8 (Ccarbene), 136.4, 135.5,
3
1
mmol, 83%). H NMR (300 MHz, CDCl ): δ 7.68−7.50 (m, 4 H, Ar−
3
135.2, 134.3, 134.2, 129.4, 128.5, 128.4, 123.6, 123.6, 122.7, 113.3,
11.8, 111.1 (Ar−C), 54.5 (NCH), 54.5 (NCH), 53.2 (NCH Ph),
H), 7.47−7.28 (m, 5 H, Ar−H), 7.24−7.13 (m, 4 H, Ar−H), 6.23
1
2
3
(
sept, J
= 7 Hz, 1 H, NCH), 6.12 (s, 2 H, NCH Ph), 5.99 (sept,
H−H 2
48.0 (NCH ), 36.0 (SCH), 30.5 (SCH ), 28.9 (CH ), 24.1 (CH ),
2 2 2 3
3
JH−H = 7 Hz, 1 H, NCH), 5.13−5.02 (m, 2 H, NCH ), 3.50−3.38 (m,
H, SCH ), 3.13 (sept, J
2
21.8 (CH ), 21.5 (CH ). Mp: 95 °C. Anal. Calcd for C H Br N PdS:
3 3 33 42 2 4
3
3
2
= 7 Hz, 1 H, SCH), 1.86 (d, J
= 7 Hz, 6 H, CH ) 1.37 (d, J
= 7
= 7
C, 49.98; H, 5.34; N, 7.07. Found: C, 50.04; H, 5.39; N, 7.07. MS
2
H−H
H−H
3
3
+
Hz, 6 H, CH ), 1.65 (d, J
(ESI): m/z 713 [M − Br] .
3
H−H
3
H−H
13
1
Hz, 6 H, CH3). C{ H} NMR (125 MHz, CDCl ): δ 184.5 (Ccarbene),
trans-Dibromido(1-isobutyl-3-(2-(isopropylthio)propyl)-
benzimidazolin-2-ylidene)(1,3-diisopropylbenzimidazolin-2-
ylidene)palladium(II) (17). The compound was prepared in analogy to
3
1
1
5
78.6 (Ccarbene), 136.2, 135.3, 135.2, 134.3, 134.2, 129.5, 128.6, 128.5,
23.8, 123.7, 122.7, 113.4, 113.3, 112.0, 110.9 (Ar−C), 55.4 (NCH),
4.8 (NCH), 54.4 (NCH Ph), 49.1 (NCH ), 36.2 (SCH), 30.5
13 from 8 (371 mg, 1.00 mmol, 1.00 equiv), silver(I) oxide (116 mg,
2
2
i
(
SCH ), 24.4 (CH ), 21.8 (CH ) 21.6 (CH ). Mp: 224 °C (dec).
0.50 mmol, 0.50 equiv), and [PdBr
2
( Pr
2
-bimy)]
2
(469 mg, 0.50 mmol,
2
3
3
3
Anal. Calcd for C H Br N PdS·CH Cl : C, 45.88; H, 4.90; N, 6.49.
0.50 equiv). The product was obtained as a yellow solid (541 mg, 0.71
3
2
40
2
4
2
2
+
1
Found: C, 46.30; H, 4.58; N, 6.73. MS (ESI): m/z 699 [M − Br] .
trans-Dibromido(1-isobutyl-3-(2-(isopropylthio)ethyl)-
benzimidazolin-2-ylidene)(1,3-diisopropylbenzimidazolin-2-
ylidene)palladium(II) (14). The compound was prepared in analogy to
mmol, 71%). H NMR (500 MHz, CDCl
3
): δ 7.63−7.60 (m, 2 H, Ar−
H), 7.54−7.51 (m, 1 H, Ar−H), 7.45−7.41 (m, 1 H, Ar−H), 7.31−
3
7.28 (m, 2 H, Ar−H), 7.26−7.23 (m, 2 H, Ar−H), 6.35 (sept, J
=
H−H
H−H
3
3
7 Hz, 1 H, NCH), 6.27 (sept, J
= 7 Hz, 1 H, NCH), 4.99 (t, J
H−H
3
1
0
0
3 from 2 (391 mg, 1.00 mmol, 1.00 equiv), silver(I) oxide (116 mg,
= 7 Hz, 2 H, NCH ), 4.60 (d, J
JH−H = 7 Hz, 1 H, SCH), 3.01 (sept, J
= 7 Hz, 2 H, NCH ), 3.16 (sept,
2
H−H 2
i
3
3
.50 mmol, 0.50 equiv), and [PdBr ( Pr -bimy)] (469 mg, 0.50 mmol,
= 7 Hz, 1 H, CH), 2.80 (t,
= 7 Hz, 2 H, CH ), 1.88
2
2
2
H−H
3J
(d, J
= 7 Hz, 2 H, SCH ), 2.62 (quint, J
3
.50 equiv). The product was obtained as a yellow solid (635 mg, 0.85
H−H
2
H−H
2
1
mmol, 85%). H NMR (500 MHz, CDCl ): δ 7.62−7.56 (m, 2 H, Ar−
H), 7.45−7.39 (m, 2 H, Ar−H), 7.31−7.27 (m, 2 H, Ar−H), 7.23−
3
3
3
= 7 Hz, 6 H, CH ), 1.86 (d, J
= 7 Hz, 6 H, CH ), 1.16 (d, J
C{ H} NMR (125 MHz, CDCl ): δ 183.5 (Ccarbene), 179.6 (Ccarbene),
= 7 Hz, 6 H, CH ), 1.34
H−H
3
H−H
3
3
3
(
d, J
= 7 Hz, 6 H, CH3).
H−H
3
H−H
3
7
.19 (m, 2 H, Ar−H), 6.28 (sept, J
= 7 Hz, 1 H, NCH), 6.24
13
1
H−H
3
3
(
sept, J
= 7 Hz, 1 H, NCH), 5.06−5.01 (m, 2 H, NCH ), 4.56 (d,
H−H
2
136.1, 135.1, 134.3, 134.2, 123.4, 123.4, 122.7, 113.4, 113.3, 111.4,
3
JH−H = 8 Hz, 2 H, NCH ), 3.43−3.38 (m, 2 H, SCH ), 3.18−3.06 (m,
2
2
111.1 (Ar−C), 56.2 (NCH ), 54.6 (NCH), 48.0 (NCH ), 36.1
2
2
3
3
2
H, SCH, CH), 1.85 (d, J
= 7 Hz, 6 H, CH ), 1.84 (d, J
= 7 Hz, 6 H, CH ), 1.13 (d, J
= 7
= 7
H−H
3
H−H
(SCH), 30.5 (SCH ), 30.5 (CH), 28.9 (CH ), 24.2 (CH ), 21.8
2
2
3
3
3
Hz, 6 H, CH ), 1.35 (d, J
Hz, 6 H, CH3). C{ H} NMR (125 MHz, CDCl ): δ 183.9 (Ccarbene),
3
H−H
3
H−H
(CH ), 21.6 (CH ) 21.5 (CH ). Mp: 229 °C (dec). Anal. Calcd for
3 3 3
13
1
3
C H Br N PdS: C, 47.47; H, 5.84; N, 7.38. Found: C, 47.97; H,
30 44 2 4
1
1
4
79.3 (Ccarbene), 136.1, 134.7, 134.3, 134.2, 123.5, 123.5, 122.7, 113.4,
+
6.15; N, 7.63. MS (ESI): m/z 679 [M − Br] .
13.3, 111.5, 110.8 (Ar−C), 56.2 (NCH), 54.9 (NCH), 54.6 (NCH ),
2
trans-Dibromido(1-benzhydryl-3-(2-(isopropylthio)propyl)-
benzimidazolin-2-ylidene)(1,3-diisopropyl-benzimidazolin-2-
ylidene)palladium(II) (18). The compound was prepared in analogy to
9.0 (NCH ), 36.2 (SCH), 30.5 (SCH ), 30.4 (CH), 24.4 (CH ), 21.7
2
2
3
(
CH ), 21.8 (CH ) 21.4 (CH ). Mp: 235 °C (dec). Anal. Calcd for
3 3 3
1
273
dx.doi.org/10.1021/om500083r | Organometallics 2014, 33, 1266−1275